BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 11593334)

  • 21. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules.
    Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR
    Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
    Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
    J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
    Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
    Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.
    Yee C; Gilbert MJ; Riddell SR; Brichard VG; Fefer A; Thompson JA; Boon T; Greenberg PD
    J Immunol; 1996 Nov; 157(9):4079-86. PubMed ID: 8892642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
    Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL
    J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
    Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
    Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
    Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
    J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
    Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
    Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
    J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes.
    Dionne SO; Smith MH; Marincola FM; Lake DF
    Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
    Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
    Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
    Oertli D; Marti WR; Zajac P; Noppen C; Kocher T; Padovan E; Adamina M; Schumacher R; Harder F; Heberer M; Spagnoli GC
    Hum Gene Ther; 2002 Mar; 13(4):569-75. PubMed ID: 11874634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.